Looks like ARCH Venture Partners is gearing up for its ninth fund, with aims to raise $400 million, according to a regulatory filing. The Chicago-based early stage venture firm has a deep history in tech and life sciences investments – with some notable recent plays like Illumina offshoot Grail, Harvard 3D printing spinout Voxel 8, and Doug Williams’ brainchild Codiak Biosciences.